drug · antibody
BLINCYTO
updated 6mo agoby $AMGN AMGEN INC🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 4Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 12 investigational indications.
targets
B-lymphocyte antigen CD19T cell surface glycoprotein CD3
all catalysts(0)
nothing on the calendar yet
Trials studying BLINCYTO
- phase3A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- phase2A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
- phase2Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
- phase2A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- phase2A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
- phase2Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- phase3A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
- phase2Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
News(4)
- At ASH, drugmakers to showcase early data for three-pronged cancer therapiesJ&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.biopharma_dive · 11d ago
- Amgen starts MariTide autoinjector study as pivotal readouts approachWith the first Phase 3 data expected for Amgen’s MariTide next year, analysts are looking for evidence that the GLP-1 candidate is tolerable. Meanwhile, the company has begun testing an autoinjecto…biospace · 12d ago
- Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s AbogenNovartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cyto…biospace · 1mo ago
- Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engagerNovartis is paying Abogen Biosciences $575 million upfront for an mRNA-encoded T-cell engager that showed early clinical promise in autoimmune disease. The deal, which includes up to $7.2 billion i…fiercebiotech · 1mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that